Bryan Ho, MD
Neurology · Augusta, GANPI 1336280569
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (53.1%), consulting fees and speaking fees — rather than concentrated in one kind of arrangement. It is spread thinly across 25 manufacturers, the largest accounting for just 18.9%. Reporting peaked in 2019 at $4,336 and has fallen 82.5% since, to $761 in 2025.
Across 267 payments — averaging $33.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amneal Pharmaceuticals LLC$2K
- MDD US Operations, LLC$2K
- Acorda Therapeutics, Inc$1K
- AbbVie$611
- Sunovion Pharmaceuticals Inc.$583
- Acadia Pharmaceuticals Inc$558
- plus $3K from 19 others
Across 35 payments — averaging $2815.01 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$42K
- H. Lundbeck A S$28K
- Neurocrine Biosciences, Inc.$15K
- Acadia Pharmaceuticals Inc$12K
- Lundbeck LLC$1K
What the payments were for
- Consulting fees$2,43027%
- Speaking & faculty fees$1,46316%
- Food & beverage$4,76853%
- Education$3244%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amneal Pharmaceuticals LLC | 12 | $1,701 |
| MDD US Operations, LLC | 109 | $1,536 |
| Acorda Therapeutics, Inc | 6 | $1,495 |
| AbbVie(2 entities) | 6 | $611 |
| Sunovion Pharmaceuticals Inc. | 25 | $583 |
| Acadia Pharmaceuticals Inc | 2 | $558 |
| Teva Pharmaceuticals USA, Inc. | 15 | $532 |
| Supernus Pharmaceuticals, Inc. | 19 | $406 |
| UCB, Inc. | 7 | $224 |
| Biogen | 9 | $180 |
| Novartis | 8 | $166 |
| AstraZeneca | 6 | $129 |
| Johnson & Johnson | 5 | $119 |
| Amgen | 4 | $115 |
| EMD Serono, Inc. | 6 | $104 |
| Portola Pharmaceuticals, LLC | 4 | $104 |
| Grifols USA, LLC | 6 | $95 |
| CSL Behring | 4 | $85 |
| Avanir Pharmaceuticals, Inc. | 4 | $73 |
| Pfizer | 3 | $56 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $37 |
| Novocure Inc. | 2 | $24 |
| Boston Scientific | 1 | $21 |
| Shire North American Group Inc | 1 | $16 |
| SK Life Science, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,985 in reported general payments places this provider in the 75th percentile of 506 neurology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 39 | $295,053 |
| GocovriAmantadine Hcl | 56 | $190,832 |
| AustedoDeutetrabenazine | 17 | $189,787 |
| NuplazidPimavanserin Tartrate | 17 | $92,244 |
| RytaryCarbidopa/Levodopa | 66 | $82,241 |
| Emgality PenGalcanezumab-Gnlm | 44 | $31,210 |
| Nurtec OdtRimegepant Sulfate | 19 | $31,184 |
| Rasagiline Mesylate | 90 | $28,089 |
| Entacapone | 116 | $27,716 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 436 | $18,129 |
| Aimovig AutoinjectorErenumab-Aooe | 23 | $18,020 |
| QuliptaAtogepant | 14 | $14,772 |
| NeuproRotigotine | 11 | $10,340 |
| Primidone | 165 | $6,089 |
| AmantadineAmantadine Hcl | 75 | $5,307 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| MDD US Operations, LLCGocovri | $1,536 | $190,83256 claims |
| Teva Pharmaceuticals USA, Inc.Austedo | $532 | $189,78717 claims |
| Acadia Pharmaceuticals IncNuplazid | $558 | $92,24417 claims |
| Amneal Pharmaceuticals LLCRytary | $1,701 | $82,24166 claims |
| PfizerNurtec Odt | $56 | $31,18419 claims |
| AbbVieQulipta | $611 | $14,77214 claims |
| UCB, Inc.Neupro | $224 | $10,34011 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 506 neurology providers in Georgia.
Other neurology in Augusta
- John MorganAugusta$715K
- Alexis ShaeferAugusta$279K
- Kapil SethiAugusta$52K
- Colin McLeodAugusta$49K
- Debra Moore-HillAugusta$48K
- Mitzi WilliamsSmyrna$1.4M
- Joash LazarusAtlanta$1.1M
- Jeffrey EnglishAtlanta$749K
- Frank BerensonAtlanta$527K
- Julio FlaminiAtlanta$501K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.